NovaScan, a clinical stage oncology company based in Chicago, announced that it has started a human GI clinical trial for its nsCanary™ device at Texas International Endoscopy Center (TIEC), led by Principal Investigator Isaac Raijman MD. This trial will include 200 patients across several clinical areas, including upper and lower gastrointestinal lumen, pancreas and biliary tract. It is anticipated that the trial will collect the data by the Spring of 2023.
Abstract on FrostBite™ EUS-Compatible Cryocatheter Accepted for Presentation at the American College of Gastroenterology 2022 Annual Meeting
GI Cryo, Inc., a preclinical medical device development spin-off company from CPSI Biotech, will be presenting on the development and evaluation of the novel FrostBite™ endoscopic ultrasound (EUS) cryocatheter at the annual meeting for the American College of Gastroentrology (ACG2022) this October.
NovaScan, a clinical stage oncology company based in Chicago, announced that it will be presenting a poster at ACG Annual Scientific Meeting, to be held from October 21-26th at the Charlotte Convention Center in Charlotte NC.
GI Cryo completes pre-clinical evaluation of FrostBite™, a next generation minimally invasive endoscopic ultrasound compatible cryoablation catheter to treat cancer
EndoRx and DFC Medical were honored to be the primary underwriting sponsors for this diverse and dynamic group of women in a runway show like no other – a runway of role models.
NovaScan, a clinical-stage oncology company based in Chicago, has announced the appointment of luminaries in interventional pulmonology and gastroenterology to lead initiatives in lung and GI, respectively.
NovaScan, a clinical-stage oncology company based in Chicago and Milwaukee, recently had its publication titled “The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and ex vivo Patient Studies” accepted in the highly regarded peer-reviewed journal, JMIR Biomedical Engineering.
NovaScan announced that it has completed a $8 Million Series B financing, led by Builders VC. As a part of this transaction, Amit Mehta, MD, a partner at Builders, will join the Board of Directors of NovaScan.